Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223421 | 0.87 | DGAT1 (0.54) | DGAT1NR1H4 | |
| SCHEMBL16985190 | 0.81 | DGAT1 (0.49) | DGAT1 | |
| SCHEMBL3392865 | 0.79 | DGAT1 (0.55) | DGAT1 | |
| SCHEMBL3392862 | 0.79 | DGAT1 (0.55) | DGAT1 | |
| SCHEMBL14952369 | 0.79 | DGAT1 (0.45) | DGAT1NR1H4 | |
| SCHEMBL13223436 | 0.75 | DGAT1 (0.39) | DGAT1NR1H4 | |
| SCHEMBL13325032 | 0.75 | DGAT1 (0.39) | DGAT1NR1H4 | |
| SCHEMBL16053449 | 0.75 | DGAT1 (0.44) | DGAT1 | |
| SCHEMBL1424471 | 0.74 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL13223418 | 0.74 | DGAT1 (0.43) | DGAT1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185567-B1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2185567-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7718645-B2 | Substituted bicyclolactam compounds | PFIZER INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718645-B2 | Substituted bicyclolactam compounds | PFIZER INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | PFIZER INC | 2009-05-28 | — | — | US | disclosed |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | PFIZER INC | 2009-05-28 | — | — | US | disclosed |
| WO-2009016462-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | DGAT1 4238/4885NR1H4 1270/4885 |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | DGAT1 4238/4885NR1H4 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.